Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights, 2018-2028

Wednesday, July 18, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 17, 2018 /PRNewswire/ -- INTRODUCTIONParkinson's disease is a chronic disorder that gradually leads

to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer's disease) and is characterized by symptoms such as shaking, rigidity, difficulty
in walking / movement, and several other cognitive and behavioral problems. Parkinson's disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson's. The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease. Despite the availability of several types of dopamine agonists, there still are a myriad of motor and non-motor symptoms that currently available therapies are unable to treat.Read the full report: https://www.reportlinker.com/p05474510 The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well. In fact, there are multiple initiatives established by start-ups that are being backed by venture capital funding to expedite the development of potential therapeutic options for better disease management.SCOPE OF THE REPORTThe “Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights, 2018-2028” report provides an extensive study on the marketed, clinical and preclinical molecules being investigated for the treatment of Parkinson's disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in extensive detail.Figure 1.1 Parkinson's Disease: Scope and Competitive InsightsSource: Roots AnalysisAmongst other elements, the report includes:• A detailed assessment of the current market landscape of drugs being developed for the treatment of Parkinson's disease, providing information on drug developer(s), phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration.• An in-depth analysis of the product pipeline and developer companies, featuring four schematic representations; these include [A] a heptagon representation highlighting the distribution of the marketed and development stage molecules based on their mechanisms of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various molecule types and stages of development, [C] a funnel analysis highlighting the distribution of molecules (segregated by stage of development) based on route of administration and treatment type, and [D] a logo landscape of the various industry players involved in the development of drugs, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large).• An analysis highlighting the key unmet needs across Parkinson's disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.• Comprehensive profiles of drugs in phase III of clinical development, with information on the developer, specific target patient population, mechanism of action, clinical trials, current status of development, and recent developments (if available).• An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their development portfolio. For all companies that emerged as important players in this field, we have presented a five-dimensional spider web analysis, taking into account the company's size, activity on Google Trends, stage of development of lead molecule, strength of the Parkinson's disease pipeline and the (present) number of clinical trials being conducted by the player.• A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis features an ownership change matrix and presents a financial evaluation of these deals (revenues and respective deal multiples) as well.• A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers involved in the development of molecules in this domain.• An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.• A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development of anti-Parkinson's therapeutics.The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from both secondary and primary sources. The opinions and insights presented in this study were influenced by inputs (through a comprehensive survey) of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.The secondary sources of information include:• Annual reports• Investor presentations• SEC filings• Industry databases• News releases from company websites• Government policy documents• Industry analysts' viewsCHAPTER OUTLINESChapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Parkinson's disease market in the long term.Chapter 3 provides an introduction to Parkinson's disease. It provides a detailed discussion on the history, symptoms and stages of Parkinson's disease, factors influencing disease progression and the various treatment regimens that are available in the market. The section also highlights the epidemiology of the disease and its economic burden across various regions.Chapter 4 includes information on close to 190 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the drug candidates across various molecule types and stages of development, and a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type. Additionally, the chapter features a logo landscape of developers engaged in this domain, distributed on the basis of location of headquarters and size of the company.Chapter 5 highlights the key unmet needs associated with the management and treatment of Parkinson's disease. The chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across the public portals.Chapter 6 contains detailed profiles of drugs that are in phase III of clinical development. Each profile features an overview of the developer, and provides information on the status of development, target population, mechanism of action, results of clinical trials (if available) and recent developments (if available).Chapter 7 features an insightful competitive analysis, highlighting the most active players in this domain on the basis of their activity (in terms of developing therapeutics for Parkinson's disease). For each of the shortlisted companies, we have presented a spider web analysis highlighting the company's size, activity on Google, stage of development of lead molecule, strength of the Parkinson's disease pipeline and the (present) number of clinical trials being conducted by the player.Chapter 8 presents a detailed analysis of the mergers and acquisitions that have taken place in this industry. The chapter provides information on the acquiring and acquired companies (headquarters and the ownership (public / private)), along with the year of acquisition, acquiring amount (if available), and the financial status of the acquired company at the time of acquisition. It features a detailed ownership change matrix depicting the distribution of mergers and acquisitions across private firms, public firms and sole proprietorships. It also includes an evaluation of the financials of these deals (revenues of the acquired firms at the time of acquisition and their respective deal multiples).Chapter 9 provides an analysis of KOLs in the field of Parkinson's disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.Chapter 10 presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place amongst the start-ups in the period between 2010 and March 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.Chapter 11 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in development of therapeutics for Parkinson's disease. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.EXAMPLE HIGHLIGHTS1. The analysis of content presented on informal (50 patient blogs and over 12,000 social media posts) and formal (over 200 scientific literature studies) literary sources, and the opinions express by industry experts confirm the existence of a significant unmet need within the anti-Parkinson's disease therapeutics market. Some of the unaddressed concerns suggested through multiple portals include lack of disease modifying treatments, delayed diagnosis, unavailability of therapies to manage non-motor symptoms and poor quality of life.2. Over 180 product candidates are currently being evaluated across various stages of development for the management / treatment of Parkinson's disease. Of these, 55% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 7 are in phase III, 42 in phase II, and 25 in phase I and phase I/II trials. Interestingly, since 2015, four product candidates have been approved; these are (based on year of approval) OSMOLEX ER™ (2018), NUPLAZID® (2016), ONGENTYS® (2016) and Xadago® (2015).3. Majority of novel drugs (53%) are disease modifying agents, while 32% of candidate molecules are being developed for providing symptomatic relief only. Rest of the drugs are designed and being evaluated to cure Parkinson's disease. It is worth highlighting that 34% of pipeline candidates have been shown to induce therapeutic effect by inhibiting a protein / enzyme; further, 17% are dopamine agonists, while 13% are channel / receptor antagonists.4. The market landscape is characterized by the presence of large (20), mid-sized (31) and small-sized companies (91). Some of the prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) AbbVie, ACADIA Pharmaceuticals, Amgen, AstraZeneca, BIAL Group, Eli Lilly, Lundbeck, Luye Pharmaceuticals, Osmotica Pharmaceutical, Sumitomo Dainippon Pharma, UCB Pharma and Zambon. The growing unmet need within this domain has spurred the establishment of many start-ups in the recent years; examples include (in alphabetical order, no selection criteria) 4P Therapeutics, Acelot, Aeolus Pharmaceuticals, Aestas Pharma, Antoxis, BlueRock Therapeutics, BrainStorm Cell Therapeutics, Capo Therapeutics, Cellix Bio, Cerevance, Clera, Contera Pharma, Curemark, DermaXon, Domain Therapeutics, Enterin, Fabre-Kramer Pharmaceuticals, Herantis Pharma Impel NeuroPharma, Io Therapeutics, Junaxo, Living Cell Technologies, Lysosomal Therapeutics, Melior Pharmaceuticals, Minerave Neurosciences, Mission Therapeutics, Peptron, Pharma Two B, Prana Biotechnology, Priavoid, Primary Peptides, QR Pharma, Serina Therapeutics, TechnoPhage, Vivreon Biosciences and Xoc Pharmaceuticals.5. More than USD 2.2 billion has been invested in various companies, across 182 instances of funding, since 2010. The Michael J. Fox Foundation, Vinnova, Roche Venture Fund, Mérieux Développement, Alliance of Angels, Shire, Ysios Capital, Third Rock Ventures, Takeda Pharmaceutical, Sunstone Capital and Sofinnova Partners have emerged as some of the prominent investors (in terms of number of funding instances) in this market.6. Several prominent scientists (over 100 investigators evaluated) have made significant contributions in advancing the clinical development efforts and, therefore, have emerged as key opinion leaders in this field. It is worth noting that universities and hospitals, across various regions, have been conducting breakthrough research along with various KOLs to develop an efficient treatment for patients with Parkinson's disease; examples of these universities and hospitals are (in alphabetical order, no selection criteria) Addenbrookes Hospital, Auckland City Hospital, Cedars-Sinai Medical Center, Jichi Medical University and Loma Linda University of Health.7. The domain has witnessed over seven acquisitions in the recent past, highlighting that the market is partly driven by acquisition of start-ups with promising drug candidates. These include multiple big-ticket deals; a prominent example being the acquisition of Prexton Therapeutics by Lundbeck (deal valued at USD 1.1 billion) in March 2018. Interestingly, majority of the acquisition events took place in the US; however, there were several cross-border acquisitions involving start-ups based in the US and big pharmaceutical players in Japan.Read the full report: https://www.reportlinker.com/p05474510 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/parkinsons-disease-market-pipeline-review-developer-landscape-and-competitive-insights-2018-2028-300682432.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store